Even clinical interventions, such as the administration of granulocyte colony-stimulating factor (G-CSF) to mitigate neutropenia during hematopoietic stem cell transplantation, have been reported to amplify the p53-mediated DNA damage response triggered by CRISPR/Cas9-induced DSBs67. This evidence concerns the gene CSF3 and neutropenia.